Cell-based Therapies for Acute Respiratory Distress Syndrome: Where Are We Now?

Publication date: Apr 01, 2024

There is considerable interest in the potential for cell-based therapies, particularly mesenchymal stromal cells (MSCs) and their products, as a therapy for acute respiratory distress syndrome (ARDS). MSCs exert effects via diverse mechanisms including reducing excessive inflammation by modulating neutrophil, macrophage and T-cell function, decreasing pulmonary permeability and lung edema, and promoting tissue repair. Clinical studies indicate that MSCs are safe and well tolerated, with promising therapeutic benefits in specific clinical settings, leading to regulatory approvals of MSCs for specific indications in some countries. This perspective reassesses the therapeutic potential of MSC-based therapies for ARDS given insights from recent cell therapy trials in both COVID-19 and in ‘classic’ ARDS, and discusses studies in graft-vs. -host disease, one of the few licensed indications for MSC therapies. We identify important unknowns in the current literature, address challenges to clinical translation, and propose an approach to facilitate assessment of the therapeutic promise of MSC-based therapies for ARDS.

Concepts Keywords
Disease ARDS therapies
Mscs cell therapy
Pulmonary mesenchymal stem cells
Safe mesenchymal stromal cells
Therapy

Semantics

Type Source Name
disease IDO cell
disease MESH Acute Respiratory Distress Syndrome
disease MESH inflammation
disease VO macrophage
disease MESH edema
disease MESH COVID-19
disease IDO host
pathway REACTOME Translation
drug DRUGBANK Mesenchymal Stem Cells

Original Article

(Visited 1 times, 1 visits today)